Cisplatin is normally administered in chemotherapy for ovarian cancer, but is accompanied by severe dosedependent toxicity. The combination of cisplatin with other antitumor agents may be a useful alternative for achieving higher antitumor efficiency and lower toxicity. Claudin-3 (CLDN3), a commonly upregulated gene in 90% of ovarian cancers, has been identified as a novel therapeutic target of ovarian cancer. Therefore, in the present study, we constructed a recombinant plasmid carrying an shRNA targeting CLDN3 (pshCLDN3), and investigated the antitumor effects of the combination therapy of pshCLDN3 and a low-dose of cisplatin for the treatment of ovarian cancer. Heparin-polyethyleneimine (HPEI) nanogel, a novel gene carrier with superior biodegradability, excellent blood compatibility and low-toxicity, was used to deliver pshCLDN3 into ovarian cancer cells. The knockdown efficiency was determined by western blot analysis and CLDN3 immunostaining. Nude mice bearing intraperitoneal ovarian carcinomas were treated with pshCLDN3/ HPEI complexes, low-dose cisplatin, pshCLDN3/HPEI plus low-dose cisplatin or control agents, respectively. The results showed that pshCLDN3/HPEI effectively suppressed the expression of CLDN3 in ovarian cancer. The combination therapy of pshCLDN3/HPEI and low-dose cisplatin exhibited enhanced antitumor activity, when compared with either agent alone, as evidenced by mean tumor weight analysis, Ki-67 immunostaining analysis and TUNEL assay, without obvious systemic toxicity. These results indicate that pshCLDN3/HPEI combined with low-dose cisplatin demonstrates apparent synergistic antitumor activity without marked toxicity. Our study offers a novel therapeutic strategy for the treatment of ovarian cancer.
Introduction
Ovarian cancer remains the leading cause of death among gynecologic malignancies and accounts for 6% of all cancer-related deaths in females in the US (1) . Cisplatin, as a first-line agent of cytotoxic chemotherapy for ovarian cancer is widely used in clinical practice. However, severe dosedependent toxicity, such as nephrotoxicity, neurotoxicity and ototoxicity, often cause patient intolerance (2, 3) . Achieving the highest antitumor efficiency using the lowest possible dose is a challenging problem in the clinic. A strategy using dual agents rather than a single agent may have enormous potential for solving this issue.
Claudins (CLDNs) are a family of 17-to 27-kDa integral membrane proteins forming tight junctions (TJs) (4) (5) (6) . Previous studies have revealed that claudin-3 (CLDN3) and claudin-4 (CLDN4) are overexpressed in ovarian cancer (7) (8) (9) (10) (11) and their abnormally high expression enhances tumor cell motility, invasion and survival (12) . Conversely, in vitro siRNA inhibition of CLDN3 and CLDN4 expression in ovarian cancer cells was found to reduce tumor cell invasion (12) . An in vivo study carried out in our laboratory showed that silencing of the CLDN3 gene with short hairpin RNA (shRNA) significantly inhibited the growth of ovarian tumors (13) . These findings suggest the importance of CLDN3 and CLDN4 as novel therapeutic targets of ovarian cancer. Furthermore, chemotherapy-resistant ovarian tumors were reported to express CLDN3 and CLDN4 genes at significantly higher levels when compared with chemotherapy-sensitive ovarian tumors (14) . Thus, downregulation of CLDN4 expression may increase the chemosensitivity of ovarian cells to cisplatin (15) . As a result, in the present study, we combined CLDN3 suppression with a low-dose of cisplatin for the treatment of ovarian cancer, to investigate whether there is a synergistic effect between CLDN3 suppression and cisplatin, and to develop a low toxic and novel therapeutic strategy against ovarian cancer.
The gene delivery system is the crucial factor that influences the efficiency of CLDN3 suppression. Traditional cationic polyethyleneimine (PEI) has become one of the most efficient non-viral gene carriers (16) (17) (18) . Yet, it is not biodegradable. Moreover, its transfection efficiency is strongly correlated to its cytotoxicity, and both efficiency and cytotoxicity increase when the chain length of PEI increases (19, 20) . In order to overcome these issues, we coupled short PEI chains into longer ones using heparin, resulting in biodegradable heparinpolyethyleneimine (HPEI) nanogels which have been proven to be efficient and low toxic in our previous studies (21) (22) (23) .
In the present study, we used HPEI nanogels to deliver the plasmid expressing shRNA targeting CLDN3 (pshCLDN3) into SKOV3 human ovarian cancer cells to reduce the expression of CLDN3. Moreover, we evaluated the antitumor effects of the combination therapy of pshCLDN3/HPEI complexes and low-dose cisplatin in the treatment of ovarian cancer. Our results showed that the combination therapy exhibited an enhanced antitumor efficacy, compared with either agent alone, without obvious systemic toxicity.
Materials and methods
Plasmid vector construction. As described in our previous study (13) , shRNA primers targeting CLDN3 (sense, 5'-TCCCGCAACATCATCACGTCGCATTCAAGACGTGC GACGTGATGTGTTGCTTTTTTG-3' and antisense, 5'-AGC TCAAAAAAGCAACATCATCACGTCGCACGTCTTGAA TGCGACGTGATGATGTTGC-3') were designed and synthesized. We used the HK sequence which has no homology with any of the known mammalian gene sequences as the negative control. The above sequences were then transferred into the pGenesil-2.1 vector (Genesil, Wuhan, China), which contains a kanamycin-resistance gene. The resulting recombinant plasmids were named pshCLDN3 or pshHK, respectively. Both of the two constructs were validated by DNA sequencing. The plasmids were purified using the EndoFree Plasmid Giga kit (Qiagen, Chatsworth, CA, USA) from DH5α Escherichia coli transformants.
Cell culture. The human ovarian serous cystadenocarcinoma cell line SKOV3 (ATCC, Manassas, VA, USA) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin) in a humidified atmosphere containing 5% CO 2 at 37˚C.
Plasmid transfection. Plasmid transfection was carried out using HPEI nanogels synthesized at the State Key Laboratory of Biotherapy and Cancer Center as previously described (21) . Briefly, SKOV3 cells (2x10 5 /well) were seeded in 6-well plates one day prior to transfection to achieve 80% confluence at the time of transfection. Plasmid (pshCLDN3 or pshHK)/HPEI complexes (1 µg plasmid/10 µg HPEI) were prepared in 1 ml DMEM without serum and antibiotics. An equal volume of normal saline (NS) prepared in 1 ml DMEM was used as a control agent. Cells were incubated with NS, HPEI nanogels, pshHK/HPEI complexes or pshCLDN3/HPEI complexes for 6 h, and then the medium was replaced with 2 ml complete medium (DMEM containing 10% FBS) and further incubated for 72 h.
Western blot analysis. Cells or tumor tissue samples were lysed in RIPA lysis buffer containing proteinase inhibitor (1 mM cocktail plus 1 mM PMSF). The supernatant was collected, and the protein concentration was quantified using Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Equal amounts of protein (20 µg) were loaded onto 12% SDS-PAGE gel for electrophoresis and blotted onto a PVDF membrane (Millipore, Bedford, MA, USA). Subsequently, the membrane was blocked in 5% skimmed milk for 2 h, and then incubated with rabbit anti-human polyclonal antibody against CLDN3 (1:200; Invitrogen) at 4˚C overnight, followed by horseradish peroxidase-conjugated secondary antibody. The immunoreactive bands were visualized by chemiluminescence detection. GAPDH served as the protein loading control.
Intraperitoneal carcinomatosis model. The following procedures for the animal experiments were approved by the Institutional Animal Care and Use Committee of Sichuan University. Pathogen-free female athymic BALB/c nude mice, 6-8 weeks of age, were used to establish the intraperitoneal carcinomatosis model as previously described (24) .
Briefly, SKOV3 cells (5x10 6 ) in 0.1 ml serum-free DMEM were injected s.c. into the right flank of 5 mice. Tumors were collected and minced into small particles (diameter ≤1 mm), when the tumor diameter reached ~1 cm. The small tumor particles were then resuspended in serum-free DMEM to reach a final volume of 15 ml. Thirty nude mice were inoculated i.p. with 0.5 ml of the above tumor particle suspension, respectively.
Therapy studies in vivo.
To explore the therapeutic efficacy of pshCLDN3/HPEI plus cisplatin, we treated the mice 7 days after inoculation. The mice were randomly divided into 6 groups (5/group), and received the following intraperitoneal (i.p.) administration: (i) 100 µl normal saline (NS); (ii) 50 µg HPEI nanogels in 100 µl NS, every two days for 12 times; (iii) 5 µg pshHK/50 µg HPEI complexes in 100 µl NS every two days for 12 times; (iv) 5 µg pshCLDN3/50 µg HPEI complexes in 100 µl NS, every two days for 12 times; (v) 100 µl of cisplatin, weekly for 4 times (3 mg/kg; Qinu Pharmacy Corporation, China); (vi) 5 µg pshCLDN3/50 µg HPEI complexes in 100 µl NS for 12 times and 100 µl of cisplatin (3 mg/kg) for 4 times. The dose of cisplatin used in this study was 3 mg/kg, since it was previously reported that treatment with 3 mg/kg cisplatin was well tolerated, and did not lead to a complete response but significantly inhibited tumor growth in an ovarian cancer model (25, 26) .
Two days after the last intraperitoneal injection, mice were sacrificed, and the intraperitoneal tumors were collected and weighed. At the same time following sacrifice, the location of the macroscopic tumors of each mouse was carefully observed and recorded. Tumors were divided into two parts. One was fixed in 10% formalin (pH 7.0) and embedded in paraffin. The other was stored at -80˚C for protein extraction.
Histological analysis. Paraffin-embedded intraperitoneal tumors were cut into 3-to 5-µm sections. Apoptosis was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay according to the manufacturer's instructions (Promega, Madison, WI, USA). Cell nuclei presenting dark green fluorescence were considered to be TUNEL-positive nuclei. The apoptosis index was determined by calculating the average percentage of TUNELpositive cells in 5 random fields from 3 different sections at a magnification of x400.
CLDN3 and Ki-67 immunostaining were carried out with rabbit anti-human CLDN3 antibody (1:100; Invitrogen) and rabbit anti-human Ki-67 antibody (1:100; Thermo Scientific), respectively. Briefly, tumor sections were first deparaffinized, rehydrated and incubated with 3% H 2 O 2 for 10 min. Then, antigen retrieval was conducted using 10 mM citrate buffer (pH 8.0). After blocking for 15 min with normal rabbit serum, sections were incubated with the primary antibody, followed by biotinylated secondary antibody and the streptavidin-biotin complex, successively. Detection was performed using diaminobenzidine (DAB) peroxide solution, and then the cellular nuclei were counterstained with hematoxylin. The proliferation index was determined by calculating the average percentage of Ki-67-positive cells with brown-staining nuclei in 5 random fields from 3 different sections at a magnification of x400.
Assessment of toxicity.
Health correlated indices such as weight loss, anorexia, diarrhea, cachexia, skin ulcerations or toxic death were evaluated every 4 days to evaluate the possible side-effects. Additionally, at the termination of the animal studies, the main organs (heart, liver, spleen, lung and kidney) were fixed in 10% formalin (pH 7.0), embedded in paraffin, and then cut into 3-to 5-µm sections for H&E staining.
Statistical analysis.
Values are expressed as means ± SD. ANOVA and the Student-Newman-Keuls test were used for comparisons. P<0.05 was considered to indicate a statistically significant result.
Results

Suppression of CLDN3 expression by pshCLDN3/HPEI complexes in SKOV3 ovarian cancer cells in vitro.
Evaluation of CLDN3 expression in the SKOV3 cells was performed by western blot analysis 72 h after transfection. As shown in Fig. 1A , a marked reduction in CLDN3 expression was noted in the cells transfected with the pshCLDN3/HPEI complexes, whereas no apparent alteration in CLDN3 expression was observed in cells transfected with the pshHK/HPEI complexes or the HPEI nanogels, when compared with that in the blank control (NS).
Suppression of CLDN3 expression by pshCLDN3/HPEI complexes in vivo.
We investigated whether pshCLDN3/HPEI complexes reduce the expression of CLDN3 in vivo. The intraperitoneal tumors were harvested for western blot analysis and immunohistochemistry at the termination of the animal experiments. Similar to the in vitro culture, the pshCLDN3/HPEI complexes markedly reduced the expression of CLDN3 (Fig. 1B) , whereas the pshHK/HPEI complexes or HPEI nanogels had no discernible effect on CLDN3 expression. Similar results were observed with immunohistochemistry (Fig. 1C) .
Enhanced antitumor efficacy of the combination regimen of the pshCLDN3/HPEI complexes and low-dose cisplatin.
At the termination of the animal studies, the mice were sacrificed, and the location of the macroscopic tumors was carefully observed. In the NS, HPEI and pshHK/HPEI groups, each mouse developed intraperitoneally macroscopic tumor nodules scattered on various viscera. A number of tumors were observed not only deposited on the surface of the liver, but also invading the parenchyma. In the other 3 groups, the intraperitoneal tumor nodules were localized. Tumor invasion in tissues and organs was not obvious in these groups. Next, the intraperitoneal tumors were harvested and weighed. As showed in Fig. 2 , the mean tumor weight was 1.35±0.21, 1.29±0.18, 1.16±0.14, 0.45±0.13, 0.40±0.11 and 0.17±0.07 g in the NS, HPEI nanogel, pshHK/HPEI complex, pshCLDN3/HPEI complex, low-dose cisplatin and pshCLDN3/HPEI complex plus low-dose cisplatin group, respectively. The data showed that the pshCLDN3/HPEI complexes or low-dose cisplatin alone significantly inhibited tumor growth, compared with the control therapies (P<0.05). Furthermore, the combination of pshCLDN3/HPEI and cisplatin had a superior antitumor effect, compared with pshCLDN3/HPEI or cisplatin alone (P<0.05). No significant difference in tumor weight was found among the control groups (P>0.05).
Inhibition of proliferation in vivo.
Ki-67 immunostaining was used to evaluate the tumor cell proliferation in each group. As shown in Fig. 3A and B, both the pshCLDN3/HPEI complexes and low-dose cisplatin monotherapy group exhibited weak staining for Ki-67, when compared with the control groups (P<0.05). No significant difference in Ki-67 staining was visible in the two groups (P>0.05). Moreover, the percentage of Ki-67-positive cells was significantly reduced in the combination therapy group, when compared with the percentage in the pshCLDN3/HPEI or low-dose cisplatin monotherapy group (P<0.05).
Induction of apoptosis in vivo.
We used TUNEL assay to detect apoptotic cells in the tumor tissues of each group. The results showed that both the pshCLDN3/HPEI and cisplatin monotherapy resulted in a significant increase in apoptotic tumor cells when compared with that following treatment with the control agents (P<0.05). Tumors in the combination therapy group showed an increased number of positive nuclei, when compared with the number in the pshCLDN3/HPEI or low-dose cisplatin monotherapy group (P<0.05). However, positive nuclei were rare in the control groups ( Fig. 3A and C) . Observation of toxicity. In the present study, no gross abnormalities were observed in any group. As shown in Fig. 4 , although the mean body weights in the two cisplatin-treated groups were less than that in the other four groups after the treatment course, the differences did not reach statistical significance (P>0.05). Furthermore, no pathologic change in the heart, liver, spleen, lung or kidney was noted by microscopic examination after the administration of pshCLDN3/HPEI or pshCLDN3/HPEI plus cisplatin.
Discussion
In the present study, we demonstrated that pshCLDN3/HPEI complexes effectively inhibited ovarian tumor growth, reduced tumor cell proliferation and increased tumor cell apoptosis. In addition, from the differences in the tumor location among the groups, we inferred that pshCLDN3/HPEI complexes also inhibited ovarian tumor invasion. These findings are consistent with a previous study carried out in our laboratory, in which pshCLDN3 was delivered by polyp(lactic-co-glycolic acid) (PLGA) (13) , and another study carried out by Huang et al (27) . Moreover, in the present study, the combination therapy of pshCLDN3/HPEI and low-dose cisplatin exhibited enhanced antitumor activity, compared with either agent alone, as evidenced by analysis of the mean tumor weight, Ki-67 immunostaining analysis and TUNEL assay, indicating that there may be a synergistic effect between CLDN3 suppression and cisplatin in the treatment of ovarian cancer. The combination therapy holds much promise as an effective strategy against ovarian cancer.
In addition to efficacy, the safety of therapy is an important factor in considering its utility for clinical application. It has been reported that CLDN3 is also expressed in several other normal organs and tissues (28, 29) . Systemic administration of pshCLDN3/HPEI may interfere with the expression of CLDN3 in these tissues, thus, causing various unpredictable side-effects. Therefore, in the present study, we utilized the i.p. route for pshCLDN3/HPEI administration, which may reduce the adverse effects of silencing CLDN3 in normal tissues that reside outside the peritoneum. Moreover, considering the severe side-effects owing to a high dose of cisplatin, we used a low-dose of cisplatin (3 mg/kg) in this study. Although the final mean body weights in the two cisplatin-treated groups were less than that in the other four groups, the differences did not reach statistical significance (P>0.05). Overall, the i.p. administration of pshCLDN3/HPEI combined with lowdose cisplatin was well tolerated, with no obvious toxicity throughout the course of treatment, and macroscopic examination of vital organs was normal at sacrifice. These results indicate that the combination therapy of pshCLDN3/HPEI and low-dose cisplatin has low toxicity and has potential clinical application.
However, to date, the exact mechanisms of how the combination therapy exerts its effect remain unclear. Two possible mechanisms may be involved. First, the enhanced antitumor effect may result from the enhanced activity of induced apoptosis. In the present study, we observed a higher number of apoptotic cells in the tumors treated with pshCLDN3/HPEI plus cisplatin, compared with the pshCLDN3/HPEI or cisplatin alone group (Fig. 3A and C) . Cisplatin is a well-known DNA damaging agent. It has the capability to form platinum-DNA adducts which activate several cellular processes, ultimately leading to cell cycle arrest, transcription inhibition and cell apoptosis (30) (31) (32) . Suppression of CLDN3 in ovarian cancer cells has also been found to induce cell apoptosis (13, 27) . Thus, there may be a common synergistic apoptotic pathway between pshCLDN3/HPEI and cisplatin. Second, the enhanced antitumor effect may result from the increased penetration of cisplatin into tumor tissues. Tight junctions (TJs) act as a barrier and regulator of the passage of molecules and ions between cells. CLDNs, as the major component of TJs, influence barrier functions. It has been suggested that CLDN suppression in tumor cells increases TJ permeability, thus, increasing the penetration of chemotherapeutic agents into tumor tissues, resulting in greater effectiveness of the chemotherapeutic agents (15, 33) . Therefore, we infer that pshCLDN3/HPEI increases the penetration of cisplatin into ovarian tumor tissues, and consequently enhances the antitumor effect of cisplatin. Moreover, CLDNs are transmembrane proteins and are associated with the membrane permeability of molecules. A recent study using fluorescence-labeled cisplatin showed that downregulation of CLDN4 expression in ovarian cancer cells in vitro resulted in an increased cellular accumulation of fluorescence-labeled cisplatin, indicating that CLDN suppression may also affect the transmembrane transportation of cisplatin, and consequently enhance its antitumor effect (15) . However, the precise mechanisms by which pshCLDN3/HPEI plus cisplatin exerts its effect require further investigation.
The application of gene therapy in cancer treatment depends on a safe and efficient gene delivery system. Although viral carriers have high transfection efficiency, they consistently cause severe side-effects (34) . In contrast, non-viral gene carriers such as cationic lipids and cationic polymers have many advantages, including the ease of production, low immunogenicity, and feasibility of delivering larger DNA molecules (35, 36) . However, toxicity also hinders their applications (37) . In our previous studies, we developed a novel non-viral gene delivery system using HPEI nanogels. Different from traditional PEI, HPEI nanogels are biodegrad- Figure 4 . Body weights of the mice in each group. Mice were weighed every 4 days. Although the mean body weights in the two cisplatin-treated groups were less than that in the other 4 groups after the treatment course, the differences was not statistically significant (P>0.05). Data are expressed as the means ± SD. NS, normal saline; HPEI, heparin-polyethyleneimine; CLDN3, claudin-3 able. Moreover, they are less toxic, and have a better blood compatibility (21, 22) . Based on these advantages, we used HPEI nanogels as the gene carrier in our present study. Our data showed that pshCLDN3/HPEI complexes significantly reduced the expression of CLDN3 in vitro and in vivo, indicating that HPEI nanogels efficiently deliver pshCLDN3 into SKOV3 human ovarian cancer cells. No apparent cytotoxicity and systemic toxic effects of HPEI nanogels were found in this study. pshCLDN3 delivered by HPEI nanogels showed an excellent tolerance throughout the treatment process.
In conclusion, our data showed that pshCLDN3/HPEI complexes obviously inhibited the growth of ovarian cancer. The combination therapy of pshCLDN3/HPEI and low-dose cisplatin exhibited enhanced antitumor activity, when compared with either agent alone, without obvious toxicity. The HPEI nanogel as a new non-viral gene carrier exhibited high efficiency and low toxicity. Our study offers a novel and promising therapeutic strategy for human ovarian cancer.
